US/UK/Canada

Share

About Us

Arcede Pharma develops new patent-protected drug candidates with focus on chronic obstructive pulmonary disease (COPD) and severe asthma with the aim to improve quality of life, reduce suffering and prolong life expectancy. For more information about Arcede Pharma, visit www.arcedepharma.com.

Pick a time period -
Tags ( Active)

BioStock: Arcede aims for clinic with TO1

Preparations for clinical trials continue for the Lund-based drug developer Arcede Pharma. Right now, the focus is on finding the right dose and concentration of RCD405 to use in the upcoming phase I studies. January 8 to 19 is the exercise period for the TO1 warrant, which is intended to finance the preparations.Read the full article at biostock.se : https://www.biostock.se/en/2024/01/arcede-aims-for-clinic-with-to1/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: Arcede Pharma appoints acting CEO

Arcede Pharma is in full swing with the preparations for clinical studies with drug candidate RCD405. CEO Mia Lundblad has announced that she will leave her position for a more research-oriented role outside the company. Lundblad will continue as CEO until the beginning of February, when the company’s CFO Erik Magnusson will take over as acting CEO.Read the full article at biostock.se : https://www.biostock.se/en/2023/12/arcede-pharma-appoints-acting-ceo/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: Arcede proceeds to stability study in collaboration with Iconovo

Lund-based Arcede Pharma continues to advance its project with RCD405. The company recently concluded the toxicology program and can now announce that the collaboration on the formulation work with Iconovo is progressing with good results. The formulation work has been completed and the next step will be to conduct a technical stability study and then take the drug candidate into the clinic.Read the full article at biostock.se : https://www.biostock.se/en/2023/11/arcede-proceeds-to-stability-study-in-collaboration-with-iconovo/ This is a press release from

Arcede Pharma and Iconovo take the next step in the development of a new treatment for COPD

Arcede Pharma, which develops inhalation treatments for COPD and severe asthma, and Iconovo AB (publ), which develops complete inhalation products for a global market, announce today that the collaborative project around Arcede's drug candidate RCD405 is progressing with good results. The next step in the project is a technical stability study before the drug candidate can be tested clinically.The project supported by SweLife is part of the previously communicated collaboration between Arcede Pharma, Iconovo and Lund University for the development of the drug candidate RCD405 primarily for

BioStock: Arcede Pharma approaches clinical trial after toxicological results

Lund-based Arcede Pharma has now completed the last major preclinical milestone with RCD405. The results from the final part of the toxicology program showed that the drug candidate was well tolerated. This leaves the door open to initiating clinical studies.Read the full article at biostock.se : https://www.biostock.se/en/2023/11/arcede-pharma-approaches-clinical-trial-after-toxicological-results/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: Arcede Pharma’s CEO on the right issue outcome

After this summer’s rights issue, Lund-based Arcede Pharma is now ready to continue work on the drug candidate RCD405. The issue was subscribed to approximately 72 per cent, which means that the company now has enough funds to continue development at an even pace. At the same time, the majority of the guarantors chose payment in newly subscribed units, a sign that they have great confidence in the company’s future. BioStock reached out to CEO Mia Lundblad to hear her thoughts on the outcome of the rights issue.Read the full article at biostock.se : https://

BioStock: Arcede hopes to reach larger market than existing drugs

Lund-based Arcede Pharma quietly been working away on the drug candidate RCD405 during the second quarter. The second part of the toxicology study is now underway, while the company is continuing preparations for the future beyond preclinical development. BioStock contacted CEO Mia Lundblad to find out more about what is happening in the company.Read the full article at biostock.se : https://www.biostock.se/en/2023/08/arcede-hopes-to-reach-larger-market-than-existing-drugs/ This is a press release from BioStock - Connecting Innovation & Capital. https://

BioStock: Arcede approaching dosing in tox study

When reporting on first quarter of 2023, Arcede Pharma have an eventful period to look back on. Now all eyes are on the final part of the toxicology programme, where dosing starts in June. BioStock contacted CEO Mia Lundblad to hear her thoughts on the past quarter.Read the full article at biostock.se : https://www.biostock.se/en/2023/05/arcede-approaching-dosing-in-tox-study/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: RSV drugs give hope to COPD patients

RSV infections can lead to serious conditions for patients with impaired lung capacity, such as COPD patients. Today there are no treatments for the virus, but that is soon about to change. BioStock takes a closer look at this respiratory illness and the drug candidates that are advancing towards market approval.Read the full article at biostock.se : https://www.biostock.se/en/2023/04/rsv-drugs-give-hope-to-copd-patients/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: Arcede Pharma and Iconovo receive funding from Swelife

Arcede Pharma, Iconovo and Lund University has received just over 2 MSEK from Swelife for the development of the inhaled treatment RCD405 for COPD and severe asthma. The grant will be used to develop an inhalation product for use in clinical studies and continue to study the candidate’s dual mechanism of action.Read the full article at biostock.se: https://www.biostock.se/en/2023/04/arcede-pharma-and-iconovo-receive-funding-from-swelife/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Funding received from Swelife for the development of a new treatment for COPD and severe asthma

Arcede Pharma AB announces that a consortium consisting of Arcede Pharma, Iconovo and Lund University has received just over SEK 2 million from Swelife.The project entitled "RCD405: New treatment paradigm for patients with COPD" receives a total of SEK 2 million to develop a dry powder formulation and an inhalation product based on the inhaler ICOone® for use in clinical phase I studies and to further characterize the mechanism of action of the drug candidate RCD405, which is intended for the treatment of COPD and severe asthma. The treatment is both bronchodilating and anti-inflammatory,

BioStock: Update from Arcede Pharma CEO

Arcede Pharma develops RCD405, a dual-action drug candidate for the treatment of COPD and severe asthma. The company is underway with the final part of the preclinical development, where it is waiting for final results from the toxicology program. Recently, the team was expanded with two scientific advisors, both leading experts in the respiratory field. In an interview in connection with the BioStock Investor Meeting, Arcede Pharma’s CEO Mia Lundblad gave an update.See the full interview at biostock.se : https://www.biostock.se/en/2023/03/update-from-arcede-

Notice of allowance for patent application regarding RCD405 in the US

Arcede Pharma announces that the patent application for RCD405 has been allowed by a formal notice of allowance from the United States Patent and Trademark Office.The patent relates to new molecules with a certain structure that can be used to treat diseases characterized by airway contractions, e.g. COPD, asthma, inflammation and/or vasoconstriction (American patent application No: 17/255,264; NOVEL BRONCHODILATING HETERO-LINKED AMIDES). After formal fees are paid, the patent will be granted, giving Arcede Pharma market exclusivity in the US at least until 2039. Patents have previously

BioStock: Arcede Pharma looks ahead with strengthened team

On Monday, Arcede Pharma released its report for the third quarter of the shortened fiscal year 2022. While waiting to start the final part of the toxicology program, two leading experts in the respiratory field have joined the company as advisors. BioStock contacted CEO Mia Lundblad to find out more.Read the full article at biostock.se : https://www.biostock.se/en/2023/02/arcede-pharma-looks-ahead-with-strengthened-team/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Notice of allowance for patent application of RCD405 in Canada

Arcede Pharma announces that the patent application for RCD405 has been allowed by a formal notice of allowance from the Canadian Intellectual Property Office.The patent relates to new molecules with a certain structure that can be used to treat diseases characterized by airway contractions, e.g. COPD, asthma, inflammation and/or vasoconstriction, leading to for example high blood pressure (Canadian patent application No: 3,100,835, NOVEL BRONCHODILATING HETERO-LINKED AMIDES). After formal fees are paid, the patent will be granted, giving Arcede Pharma market exclusivity in Canada through

Leading experts within pulmonary medicine and pulmonary pharmacology have been engaged as advisors to Arcede Pharma

Clive Page, Professor at Kings College in London, and Arne Egesten, Professor and Head of Pulmonary Medicine, Allergology and Palliative Medicine at Lund University, will advise Arcede Pharma as key opinion leaders (KOLs).We are very pleased that both professors have accepted to be engaged with Arcede Pharma as advisors. Their proven experience and expertise in the field will strengthen the further development of RCD405. The collaboration will ensure that our plans are critically scrutinised and will help refine our development strategies. This will be of great importance, especially in the

BioStock: Arcede Pharma prepares for clinical studies

The second Advent candle had just been lit when Lund-based Arcede Pharma released its Q2 report for the fiscal year 2022. The company is busy working on the the final parts of the toxicology program, whilst at the same time preparing the drug candidate RCD405 for clinical studies. BioStock talked to Arcede Pharma’s CEO Mia Lundblad about her view of the past quarter and what is next for the company.Read the full article at biostock.se: https://www.biostock.se/en/2022/12/arcede-pharma-prepares-for-clinical-studies/ This is a press release from BioStock - Connecting Innovation & Capital.

BioStock: Arcede Pharma’s RCD405 well tolerated

Lund-based Arcede Pharma is working hard to complete the preclinical work on the drug candidate RCD405. The company now reports the first part of the toxicological program and notes that the substance is well tolerated. BioStock contacted the company’s CEO Mia Lundblad to find out more about what this means for the project and about the next step.Read the full article at biostock.se: https://www.biostock.se/en/2022/11/arcede-pharmas-rcd405-well-tolerated/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: Arcede Pharma share under pressure despite development progress

Lund-based Arcede Pharma has had a tough start to its journey as a listed company after the spin-off from Respiratorius this summer. The ice cold stock market environment has weighed on the company’s shares. At the time of writing, the share is trading at well below Arcede Pharma’s cash position, despite the fact that the development is going according to plan. Here, BioStock looks closer at how the market values the potential that the company believes is present in the research.Read the full article at biostock.se: https://www.biostock.se/en/2022/11/arcede-pharma-share-under-pressure-

BioStock Investor Meeting: Interview with Arcede Pharma

Arcede Pharma, which just released its first quarterly report as a separately listed company, presented at the BioStock Investor Meeting in September. In connection with the event, BioStock took the opportunity to interview the company's CEO Mia Lundblad regarding drug candidate RCD405. The candidate, which is developed to treat of COPD and severe asthma, is currently being prepared for clinical phase I.See the full interview at biostock.se:https://www.biostock.se/en/2022/09/biostock-investor-meeting-interview-with-arcede-pharma/This is a press release from BioStock - Connecting

BioStock: Arcede Pharma reports on the first quarter

After almost two months as a listed company, Arcede Pharma releases its first quarterly report. The first – and slightly shortened – quarter of the fiscal year has been marked by the spin-off from Respiratorius, but CEO Mia Lundblad also provides some operational updates. Among other things, she gives us some insight into the toxicological studies that are currently underway.Read the full article at biostock.se:https://www.biostock.se/en/2022/09/arcede-pharma-reports-on-the-first-quarter/This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe